Edition:
United States

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

21.48USD
16 Feb 2018
Change (% chg)

$-0.03 (-0.14%)
Prev Close
$21.51
Open
$21.56
Day's High
$22.03
Day's Low
$21.24
Volume
67,047
Avg. Vol
135,513
52-wk High
$30.70
52-wk Low
$9.04

Chart for

About

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $489.16
Shares Outstanding(Mil.): 22.77
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Concert Pharmaceuticals Initiates Enrollment In Second Cohort Of CTP-543 Trial

* CONCERT PHARMACEUTICALS ANNOUNCES INITIATION OF ENROLLMENT IN SECOND COHORT OF CTP-543 PHASE 2A TRIAL FOR ALOPECIA AREATA

Feb 12 2018

BRIEF-Concert Pharma Says FDA Granted Fast Track Designation To CTP-543

* FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA

Jan 12 2018

BRIEF-Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

* CONCERT PHARMACEUTICALS ANNOUNCES PATENT TRIAL AND APPEAL BOARD DID NOT INSTITUTE PGR PROCEEDING Source text for Eikon: Further company coverage:

Jan 12 2018

BRIEF-Concert Pharmaceuticals Announces Appointment Of Marc Becker As CFO

* CONCERT PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER

Dec 18 2017

BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61

* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update

Nov 09 2017

BRIEF-Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

* Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial

Nov 06 2017

BRIEF-Concert Pharma pays total of $30.8 mln to Hercules Capital

* Concert Pharmaceuticals- ‍on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8

Sep 08 2017

Earnings vs. Estimates